SCHEDULE: FMR LLC Reports 6.4% Stake in Tarsus Pharmaceuticals
Beneficial Ownership Filing
FMR LLC and Abigail P. Johnson have reported beneficial ownership of 6.4% of Tarsus Pharmaceuticals Inc.'s common stock as of September 30, 2026.
Summary
- FMR LLC and Abigail P. Johnson, through various affiliated entities, collectively beneficially own 3,143,158.20 shares of Tarsus Pharmaceuticals Inc. common stock.
- This ownership stake represents 6.4% of the class of securities.
- The filing is made under Schedule 13G, indicating passive investment intent.
- The date of the event requiring this filing is September 30, 2026.
- FMR LLC is classified as a holding company (HC), and Abigail P. Johnson is classified as an investment company (IN).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting on beneficial ownership changes without providing new operational or financial performance data.
Positives
- Significant institutional ownership by FMR LLC and Abigail P. Johnson, suggesting confidence in the company's long-term prospects.
- The filing indicates a passive investment approach, which typically does not involve seeking to control or influence the issuer's management.
Negatives
- The filing does not contain any new financial performance data or operational updates, limiting insights into the company's current health.
Risks
- While the filing indicates passive investment, any shift in FMR LLC's strategy could impact Tarsus Pharmaceuticals' stock.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding future performance.
Management Comments
- FMR LLC and Abigail P. Johnson, through their filings, certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are common for large institutional investors accumulating significant stakes in publicly traded companies, often indicating a belief in the company's value or growth potential within the pharmaceutical sector.
Comparison to Industry Standards
- FMR LLC's ownership of 6.4% is a substantial stake for a passive investor in the biotechnology/pharmaceutical sector, often seen in companies with promising pipelines or market positions.
Stakeholder Impact
- Shareholders may view the increased institutional ownership by FMR LLC and Abigail P. Johnson as a positive signal, potentially increasing investor confidence.
Next Steps
- FMR LLC and Abigail P. Johnson will continue to hold their shares in Tarsus Pharmaceuticals Inc. as per their investment strategy.
- Future filings will be made if there are material changes in beneficial ownership.
Key Dates
| Date | Description |
|---|---|
| 01/03/2023 | Effective date of Power of Attorney for FMR LLC. |
| 01/26/2023 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 09/30/2026 | Date of event which requires filing of this statement. |
| 11/04/2026 | Date of joint filing agreement and signature date. |
Keywords
Tarsus Pharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.